AbleDocs Inc. Announces the Acquisition of Diversa Docs ApS to Further Reach of the Worldwide Leader in Document Accessibility Products and Services Throughout Scandinavia
AbleDocs Inc. the leading PDF accessibility product and service provider, and Diversa Docs ApS, a recognized leader in PDF and Web Accessibility services announce their coming together to become the Scandinavian leader in PDF accessibility products and services.
With a long-standing record of collaboration, both companies’ founders and leadership teams couldn’t be more excited to leverage each other’s capabilities to offer their existing and new clients the best in PDF/UA products and services.
“Diversa Docs has consistently been recognized as a leader in excellence in delivering PDF/UA compliant and accessible PDFs, and this acquisition will allow our combined client base to benefit from the experience, and scale of our products and services throughout Scandinavia,” said AbleDocs’ President (GLOBAL), Adam Spencer. “With their amazing team and end user focused approach, they are the ideal partner for AbleDocs. With our combined effort, we can drive the creation of next-generation PDF accessibility services and solutions,” said Vice-President (SCANDINAVIA), Jens Bjerre Kirkegaard.
“Accessibility has always appealed to me because it combines a technical field with a humanistic one,” says CEO of Diversa Docs, Asbjørn Fangel-Hansen.
“Having worked for 12 years in the Danish public sector within accessibility and most recently as the owner of one of the leading companies in the field of accessibility in Denmark, I am very honored to be part of one of the absolute leading global players when it comes to accessible documents,” adds Fangel-Hansen.
The combination of AbleDocs and Diversa Docs will widen the global presence of AbleDocs for products, services, solution development, training, and localized document accessibility support across 49 languages to ensure clients receive the best offerings possible.
About Diversa Docs
Diversa Docs ApS was founded by Lars Holm-Sørensen and Asbjørn Fangel-Hansen in 2019 as a sister company to Diversa ApS. Since then, the company has developed into one of the leaders in Denmark in terms of document accessibility and the area in general.
About AbleDocs Inc.
AbleDocs was founded in 2019 as a conglomerate of PDF accessibility remediation service providers and has grown to have operations in Canada, Denmark, Germany, Switzerland, and the United States. Its founders have been making documents accessible for over 150 years combined experience and has since expanded its offerings to include a completely new approach to document accessibility strategies to include products for high volume document accessibility, document accessibility testing.
AbleDocs is the only company in the world to guarantee the compliance of every file they produce and back it with a $10,000,000 liability guarantee. Current offerings include ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord and axesPDF.
For more information, visit https://www.abledocs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005229/en/
Contact information
For media inquiries:
Gary MacKay, mediainquiries@abledocs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 01:13:00 EET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom